Head-to-head · WeighScore
AmberHealth vs Fifty 410
By GLP-1 ScorecardUpdated
Score comparison
AmberHealth has the higher recorded score — 82.9/100 to 66.3/100.
AmberHealth grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Round-$100 semaglutide nationwide, though tirzepatide runs $175 and it isn't verified.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | AmberHealth | Fifty 410 |
|---|---|---|
| WeighScore | 82.9/100 | 66.3/100 |
| Grade | B− | C |
| Site position | #24 | #213 |
| Semaglutide | $100/mo | $99/mo (all doses, compounded) |
| Tirzepatide | $175/mo | $133/mo (starting dose, compounded) |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Site position #24 · B−
Strengths
- $100 semaglutide
- All 50 states
- Both molecules
What to consider
- Independent LegitScript certification has not been verified for this review
- Tirzepatide $175
- Monitoring detail sparse
Site position #213 · C
FDAWarning letter issued to Aspen Aesthetics dba Fifty 410 in February 2026. See the FDA warning-letter database.
Strengths
- Transparent public pricing from 99 dollars per month for semaglutide
- No membership or subscription; pay only for what you need
- Compounded by FDA-registered 503A and 503B pharmacies
- Fast 24 to 48 hour provider review
- Free one to two day shipping
What to consider
- Does not bill insurance directly
- Compounded GLP-1 is not an FDA-approved finished drug
- Specific clinician credentials are not publicly disclosed
- Served-states list is not published on the site
- FDA issued Aspen Aesthetics dba Fifty 410 a warning letter in February 2026; the letter is public in FDA's warning-letter database
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.